Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ 2nd, de Cremoux P, Stenvang J, Lykkesfeldt AE. Frogne T, et al. Among authors: de cremoux p. Breast Cancer Res Treat. 2009 Mar;114(2):263-75. doi: 10.1007/s10549-008-0011-8. Epub 2008 Apr 14. Breast Cancer Res Treat. 2009. PMID: 18409071 Free PMC article.
HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.
de Cremoux P, Dalvai M, N'Doye O, Moutahir F, Rolland G, Chouchane-Mlik O, Assayag F, Lehmann-Che J, Kraus-Berthie L, Nicolas A, Lockhart BP, Marangoni E, de Thé H, Depil S, Bystricky K, Decaudin D. de Cremoux P, et al. Among authors: de the h. Breast Cancer Res Treat. 2015 Jan;149(1):81-9. doi: 10.1007/s10549-014-3233-y. Epub 2014 Dec 12. Breast Cancer Res Treat. 2015. PMID: 25503779
Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts.
Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader Ch, de Plater L, Elbaz C, Karboul N, Fontaine JJ, Chateau-Joubert S, Boudou-Rouquette P, Alran S, Dangles-Marie V, Gentien D, Poupon MF, Decaudin D. Cottu P, et al. Among authors: de plater l, de cremoux p. Breast Cancer Res Treat. 2012 Jun;133(2):595-606. doi: 10.1007/s10549-011-1815-5. Epub 2011 Oct 16. Breast Cancer Res Treat. 2012. PMID: 22002565
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.
Luporsi E, André F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A, Egele C, Poulet B, Clough KB, Crouet H, Fourquet A, Lefranc JP, Mathelin C, Rouyer N, Serin D, Spielmann M, Haugh M, Chenard MP, Brain E, de Cremoux P, Bellocq JP. Luporsi E, et al. Among authors: de cremoux p. Breast Cancer Res Treat. 2012 Apr;132(3):895-915. doi: 10.1007/s10549-011-1837-z. Epub 2011 Nov 3. Breast Cancer Res Treat. 2012. PMID: 22048814 Free PMC article. Review.
BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
Hamy AS, Bieche I, Lehmann-Che J, Scott V, Bertheau P, Guinebretière JM, Matthieu MC, Sigal-Zafrani B, Tembo O, Marty M, Asselain B, Spyratos F, de Cremoux P. Hamy AS, et al. Among authors: de cremoux p. Breast Cancer Res Treat. 2016 Oct;159(3):499-511. doi: 10.1007/s10549-016-3961-2. Epub 2016 Sep 3. Breast Cancer Res Treat. 2016. PMID: 27592112
167 results